Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs

Area of Science:

• Public Health
• Vaccinology
• Gynecologic Oncology

Background:

• Cervical cancer remains a significant global health burden, particularly in low- and middle-income countries.
• Human papillomavirus (HPV) vaccination is a key strategy for disease prevention, but its implementation is uneven.
• Disparities in vaccine introduction highlight the need to address access and delivery challenges.

Purpose of the Study:

• To review the efficacy and effectiveness of HPV vaccines based on clinical trials and population studies.
• To evaluate the safety profile of HPV vaccines from large-scale surveillance data.
• To identify challenges and potential solutions for global HPV vaccine introduction.

Main Methods:

• Systematic review of clinical trial data on HPV vaccine efficacy and effectiveness.
• Analysis of population-based studies assessing vaccine impact.
• Review of safety data from post-marketing surveillance systems.

Main Results:

• HPV vaccines demonstrate near 100% efficacy in HPV-negative young women (<25 years) with a three-dose schedule, providing protection against persistent infection and precancerous lesions.
• Sustained protection up to 12 years has been observed, with cross-protection noted for the bivalent vaccine.
• Extensive safety data from over 270 million distributed doses show no association with serious adverse events.
• Vaccine introduction remains slow, with most high-income countries leading adoption.

Conclusions:

• HPV vaccines are highly effective and safe for cervical cancer prevention.
• Addressing programmatic and economic barriers is crucial for equitable global access, particularly in underserved regions.
• Further research on alternative schedules (e.g., one-dose, younger age vaccination) may facilitate broader implementation and reduce challenges.